Bone Metastasis in Renal Cell Carcinoma Patients: Risk and Prognostic Factors and Nomograms

Overview

Journal J Oncol

Specialty Oncology

Date 2021 May 31

PMID 34054954

Citations 11

Authors

Zhiyi Fan

Zhangheng Huang

Xiaohui Huang

Affiliations

Soon will be listed here.

Abstract

Background: Bone metastasis (BM) is one of the common sites of renal cell carcinoma (RCC), and patients with BM have a poorer prognosis. We aimed to develop two nomograms to quantify the risk of BM and predict the prognosis of RCC patients with BM.

Methods: We reviewed patients with diagnosed RCC with BM in the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015. Multivariate logistic regression analysis was used to determine independent factors to predict BM in RCC patients. Univariate and multivariate Cox proportional hazards regression analyses were used to determine independent prognostic factors for BM in RCC patients. Two nomograms were established and evaluated by calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).

Results: The study included 37,554 patients diagnosed with RCC in the SEER database, 537 of whom were BM patients. BM's risk factors included sex, tumor size, liver metastasis, lung metastasis, brain metastasis, N stage, T stage, histologic type, and grade in RCC patients. Currently, independent prognostic factors for RCC with BM included grade, histologic type, N stage, surgery, brain metastasis, and lung metastasis. The calibration curve, ROC curve, and DCA showed good performance for diagnostic and prognostic nomograms.

Conclusions: Nomograms were established to predict the risk of BM in RCC and the prognosis of RCC with BM, separately. These nomograms strengthen each patient's prognosis-based decision making, which is critical in improving the prognosis of patients.

Citing Articles

Prognostic assessment of patients with bone metastatic renal cell cancer treated with palliative radiotherapy.

Makita K, Hamamoto Y, Kanzaki H, Nagasaki K, Kochi Y, Kido T Oncol Lett. 2024; 28(4):482.

PMID: 39161334 PMC: 11332580. DOI: 10.3892/ol.2024.14615.

Brown Tumor From Secondary Hyperparathyroidism Mimicking Metastatic Renal Cell Carcinoma in a Patient With End-Stage Renal Disease.

Fogwe L, Ganipisetti V, Naha K Cureus. 2024; 16(4):e59376.

PMID: 38817492 PMC: 11139052. DOI: 10.7759/cureus.59376.

The Diagnosis and Treatment Approach for Oligo-Recurrent and Oligo-Progressive Renal Cell Carcinoma.

Bekku K, Kawada T, Sekito T, Yoshinaga K, Maruyama Y, Yamanoi T Cancers (Basel). 2023; 15(24).

PMID: 38136417 PMC: 10741872. DOI: 10.3390/cancers15245873.

Development and validation of a nomogram to predict lung metastasis in patients with testicular germ cell tumors.

Li S, Xiong S, Yang L, Zheng F, Liu J, Jiang M Heliyon. 2023; 9(9):e20177.

PMID: 37809781 PMC: 10559949. DOI: 10.1016/j.heliyon.2023.e20177.

The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm.

Le Y, Xu W, Guo W Technol Cancer Res Treat. 2023; 22:15330338231165131.

PMID: 37078130 PMC: 10126632. DOI: 10.1177/15330338231165131.

References

Wood S, Brown J . Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev. 2011; 38(4):284-91. DOI: 10.1016/j.ctrv.2011.06.011. View

Chen S, Kuo P . Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci. 2016; 17(6). PMC: 4926516. DOI: 10.3390/ijms17060987. View

Guo Q, Zhang C, Guo X, Tao F, Xu Y, Feng G . Incidence of bone metastasis and factors contributing to its development and prognosis in newly diagnosed renal cell carcinoma: a population-based study. Cancer Manag Res. 2018; 10:2935-2944. PMC: 6118275. DOI: 10.2147/CMAR.S170083. View

Zolnierek J, Nurzynski P, Langiewicz P, Oborska S, Wasko-Grabowska A, Kuszatal E . Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol. 2009; 136(3):371-8. DOI: 10.1007/s00432-009-0664-7. View

Lin P, Mirza A, Lewis V, Cannon C, Tu S, Tannir N . Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007; 89(8):1794-801. DOI: 10.2106/JBJS.F.00603. View

Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G . Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. Eur J Cancer. 2018; 107:79-85. DOI: 10.1016/j.ejca.2018.10.023. View

Ranstam J, Cook J . Kaplan-Meier curve. Br J Surg. 2017; 104(4):442. DOI: 10.1002/bjs.10238. View

Zheng W, Huang Y, Chen H, Wang N, Xiao W, Liang Y . Nomogram application to predict overall and cancer-specific survival in osteosarcoma. Cancer Manag Res. 2018; 10:5439-5450. PMC: 6235004. DOI: 10.2147/CMAR.S177945. View

Motzer R, Escudier B, Tomczak P, Hutson T, Michaelson M, Negrier S . Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14(6):552-62. DOI: 10.1016/S1470-2045(13)70093-7. View

10.

Thompson R, Ordonez M, Iasonos A, Secin F, Guillonneau B, Russo P . Renal cell carcinoma in young and old patients--is there a difference?. J Urol. 2008; 180(4):1262-6. PMC: 2615196. DOI: 10.1016/j.juro.2008.06.037. View

11.

McKay R, Kroeger N, Xie W, Lee J, Knox J, Bjarnason G . Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2013; 65(3):577-84. PMC: 4123121. DOI: 10.1016/j.eururo.2013.08.012. View

12.

Fottner A, Szalantzy M, Wirthmann L, Stahler M, Baur-Melnyk A, Jansson V . Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 2010; 11:145. PMC: 2909163. DOI: 10.1186/1471-2474-11-145. View

13.

Zekri J, Ahmed N, Coleman R, Hancock B . The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001; 19(2):379-82. DOI: 10.3892/ijo.19.2.379. View

14.

Lee C, Katz J, Fearn P, Russo P . Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002; 7(4):135-40. DOI: 10.1016/s1078-1439(01)00185-5. View

15.

Alt A, Boorjian S, Lohse C, Costello B, Leibovich B, Blute M . Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011; 117(13):2873-82. DOI: 10.1002/cncr.25836. View

16.

Grunwald V, Eberhardt B, Bex A, Florcken A, Gauler T, Derlin T . An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol. 2018; 15(8):511-521. PMC: 7136176. DOI: 10.1038/s41585-018-0034-9. View

17.

Gupta K, Miller J, Li J, Russell M, Charbonneau C . Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34(3):193-205. DOI: 10.1016/j.ctrv.2007.12.001. View

18.

Kume H, Kakutani S, Yamada Y, Shinohara M, Tominaga T, Suzuki M . Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?. J Urol. 2011; 185(5):1611-4. DOI: 10.1016/j.juro.2010.12.037. View

19.

Kim S, Yoon M, Park Y, Kim M, Nam B, Park S . Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. Gastric Cancer. 2017; 21(3):453-463. DOI: 10.1007/s10120-017-0756-z. View

20.

Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni G, Hamilton R, Fleshner N . Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urol Oncol. 2017; 35(11):661.e7-661.e14. DOI: 10.1016/j.urolonc.2017.06.060. View